Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0452W HIGH $29.46
Volume
124.73 K
Value Traded
130.94 K
Short % Float
6.75%
-28.57%Week
-48.6%1 Month
-68.93%3 Month
-89.13%6 Month
-85.31%5 Year
+17.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.77 M
EPS (TTM)
-0.23
P/E Ratio
-
Ent. Value
8.17 M
Total Shares
3.43 M
Float Shares
1.52 M
Insiders
55.60%
Institutions
12.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ICCM Catalyst Timeline
Dated clinical, regulatory and corporate events for IceCure Medical Ltd.
Past FDA Catalysts and PDUFA Decisions
How ICCM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
IceCure Medical Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ICCM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ProSense® | kidney cancer | 2026-05-19 | recurrence free rate kidney cancer: 89.4%; recurrence free rate median follow up: 83.9%; median follow up years: 4.0; no residual cancer breast cancer: 100%Read More | IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class OverbookedRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ICCM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ICCM for Q2 2026. | ||||
ICCM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ICCM ranks across every disease it competes in
Competitive Position is a premium feature
See how ICCM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialICCM News
ICCM▼ -17.5%on this news· ran to -29% by day 3
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Medical has announced the addition of Legacy Health in Portland, Oregon, as a new clinical site for its ChoICE Study, which evaluates the ProSense® cryoablation technology for low-risk breast cancer. The study aims to enroll around 400 patients across multiple sites in the U.S. and is designed to generate real-world clinical data on the effectiveness of this treatment. Dr. Nathalie Johnson will lead the clinical efforts at this site, marking a significant milestone for the study.
Read more →ICCMIceCure Medical Receives Regulatory Approval to Market ProSense® in China
IceCure Medical has received Class III medical device approval from China's NMPA for its ProSense® cryoablation system. This approval allows the company to market its technology in China, marking a significant regulatory milestone. CEO Eyal Shamir emphasized the importance of this approval for expanding access to their innovative treatment options.
Read more →ICCMWest Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
IceCure Medical has received IRB approval for its ChoICE Study, which will evaluate the effectiveness of ProSense® cryoablation combined with endocrine therapy for low-risk breast cancer in patients aged 70 and older. Patient enrollment is expected to begin shortly at 30 participating sites, aiming to gather real-world data on this minimally invasive treatment option.
Read more →ICCMIceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
IceCure Medical has announced that Adventist Health Glendale will be the first U.S. clinical site for its ChoICE Study, which focuses on low-risk breast cancer cryoablation treatment. The study aims to enroll up to 400 patients and gather real-world data to enhance the clinical adoption of ProSense. Dr. Dennis Holmes will lead the site, bringing expertise in breast cancer cryoablation.
Read more →ICCMIceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
IceCure Medical Ltd. will announce its financial and operational results for the first half of 2026 on August 12, 2026. The company will hold a conference call to discuss these results and other corporate developments. IceCure specializes in minimally-invasive cryoablation technology for tumor treatment, focusing on various cancer types.
Read more →ICCM▼ -6.5%on this news
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
IceCure Medical has initiated its post-marketing ChoICE Study at the West Cancer Center in Tennessee, focusing on ProSense® cryoablation for low-risk breast cancer. The study will enroll up to 400 patients across 30 sites in the U.S. to gather real-world data supporting the treatment's adoption. This initiative follows FDA marketing authorization received in October 2025.
Read more →ICCMIceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
IceCure Medical Ltd. has expanded its U.S. sales and marketing teams due to rising demand for its ProSense® cryoablation technology. The company reported a 70% growth in its active U.S. install base following FDA marketing authorization. New systems are being added in major metropolitan areas, enhancing clinical adoption and awareness of the treatment.
Read more →ICCM▼ -14%on this news· ran to -27% by day 3
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Medical has reported increased commercial adoption of its ProSense™ cryoablation technology in Brazil following FDA clearance for treating early-stage breast cancer. The company highlighted this growth at the SOBRICE Onco 2026 conference, where leading experts discussed ongoing clinical studies. ProSense™ is gaining traction as a minimally invasive alternative to traditional surgical methods.
Read more →ICCM▼ -24.5%on this news· ran to -48% by day 3
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
IceCure Medical Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. This compliance was confirmed after the company's stock price remained at $1.00 or higher for ten consecutive business days. The matter is now considered closed by Nasdaq, reflecting positively on IceCure's market standing.
Read more →ICCMIceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
IceCure Medical has highlighted a new peer-reviewed article in the International Journal of Surgery, showcasing the advantages of cryoablation over radiofrequency ablation for early-stage breast cancer. The article emphasizes cryoablation's strong clinical outcomes and procedural benefits, including shorter procedures and minimal scarring. IceCure is preparing for the upcoming Japanese Breast Cancer Society meeting and plans to submit ProSense® for regulatory approval in Japan.
Read more →ICCM▼ -29.4%on this news· ran to -40% by day 1shared move
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
IceCure Medical Ltd. has announced a private placement of $5.5 million with a healthcare-focused institutional investor. The offering includes ordinary shares and warrants priced at $3.00 each, above the previous market price. The proceeds will be used for working capital and corporate purposes, with the closing expected shortly, subject to customary conditions.
Read more →ICCM▲ +200.5%on this newsshared move
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation following FDA clearance. This growth is attributed to heightened physician demand, clinical guideline support, and increased patient awareness. The company has successfully expanded its presence in major U.S. cities and generated more sales leads at medical conferences.
Read more →ICCM▲ +200.5%on this newsshared move
IceCure Reports 70% Growth in Active U.S. Commercial Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical Ltd. reported a 70% increase in its U.S. active commercial install base for its ProSense cryoablation system following FDA marketing authorization. The growth is attributed to rising physician demand, clinical acceptance, and greater patient awareness. The company has gained strong interest at medical society conferences, generating significantly more sales leads compared to previous years. ProSense is positioned as an effective treatment option for low-risk breast cancer patients, especially those unsuitable for surgical interventions.
Read more →ICCM▼ -30.9%on this news
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
IceCure Medical Ltd. announced a 1-for-30 reverse share split to regain compliance with Nasdaq's minimum bid price requirement. This decision, approved by shareholders, aims to increase the trading price of its ordinary shares. The split will take effect on June 4, 2026, and will not alter shareholders' percentage ownership interests.
Read more →ICCMIceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
IceCure Medical presented promising data at ECIO 2026, highlighting a 89.4% recurrence-free rate for kidney cancer patients treated with ProSense®. An independent study reported no residual cancer in breast cancer patients at 6 and 12 months post-procedure. The FDA clearance of ProSense® is driving global interest in cryoablation as a minimally invasive treatment option.
Read more →ICCMIceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
IceCure Medical Ltd. has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement. The company did not regain compliance during the initial period but has shown intent to cure the deficiency. The extension allows until November 9, 2026, for the company to meet the necessary criteria without immediate impact on its trading status.
Read more →ICCMIceCure Reports First Quarter 2026 Financial Sales Increase Substantially in the U.S. and North America
IceCure Medical Ltd. reported a notable financial performance for the first quarter of 2026, driven by a significant increase in ProSense sales in North America after the FDA clearance. Active customer accounts utilizing ProSense rose 46%, reflecting strong demand and successful regulatory milestones. Despite the positive revenue growth of approximately 26%, the company also reported a net loss of $4.27 million, which raises concerns about its ongoing financial health. The company plans to expand its sales efforts in the U.S. and conduct a post-marketing study to further boost ProSense adoption.
Read more →ICCM▼ -6.6%on this news
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
IceCure Medical Ltd. will announce its financial and operational results for Q1 2026 on May 12, 2026. The announcement will be made before the market opens, followed by a conference call at 11:00 a.m. EDT. The company specializes in cryoablation technology for tumor destruction, offering a minimally invasive alternative to surgery.
Read more →ICCM▼ -6.4%on this news· ran to -21% by day 3shared move
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
IceCure Medical showcased its ProSense® cryoablation system at the ASBrS 2026 Annual Meeting, emphasizing its role as a minimally invasive treatment for low-risk breast cancer. The company reported a significant increase in U.S. revenue for ProSense® systems and highlighted the growing clinical adoption of cryoablation. Experts at the symposium discussed the benefits of ProSense® in de-escalating breast cancer care, particularly for older patients.
Read more →ICCMDear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “ Meeting ”) of IceCure Medical Ltd. (the “ Company ”), to be held on
IceCure Medical Ltd. has announced a Special General Meeting of Shareholders scheduled for May 11, 2026. At this meeting, shareholders will vote on a proposed reverse split of the company's ordinary shares. The board of directors has recommended that shareholders vote in favor of this proposal. Shareholders of record as of April 27, 2026, will be entitled to participate, either in person or through a proxy.
Read more →About IceCure Medical Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next ICCM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime